The earnings call indicated significant progress across Xenon's pipeline, particularly with azetukalner in epilepsy and MDD. Financially, the company is well-positioned to support ongoing developments. Despite a slight delay in the X-TOLE2 study and a negative primary endpoint in the MDD study, the overall sentiment remains positive due to consistent progress and strong financial backing.

Company Guidance -

Q2 2025

During the Q1 2025 Xenon Pharmaceuticals Earnings Conference Call, the company provided guidance on several key metrics. Xenon is nearing the completion of patient recruitment for the X-TOLE2 Phase 3 study in epilepsy, with top-line results expected in early 2026. Despite a slight delay in recruitment, the company remains confident due to the consistency of key metrics with their successful Phase 2b study. Xenon anticipates having sufficient cash to fund operations into 2027, thanks to their strong fiscal management. The company is also expanding its neuroscience-focused pipeline, with multiple regulatory filings expected this year, and is preparing for the initiation of first-in-human trials for several new drug candidates. Additionally, Xenon's azetukalner has shown promising results in both epilepsy and major depressive disorder (MDD), with ongoing Phase 3 trials in MDD and plans to initiate trials in bipolar depression by mid-year.

Progress in Azetukalner Phase 3 Epilepsy Program

Patient recruitment for the X-TOLE2 study is nearing completion with top-line results anticipated early next year. The study metrics align consistently with the successful Phase 2b X-TOLE study.

Extension of Azetukalner Usage Beyond Epilepsy

Enrollment is ongoing in the first phase 3 MDD study, X-NOVA2, with the second MDD study, X-NOVA3, and the first Phase 3 study in bipolar depression on track to initiate by mid-year.

Investigator-Sponsored MDD Study Results

The study results are consistent with prior expectations, showing clear drug activity on MADRS and SHAPS, reaffirming the rationale for further development in MDD.

Financial Position and Revenue Recognition

Xenon recognized revenue of $7.5 million from a milestone payment. Cash and cash equivalents stood at $691.1 million, sufficient to fund operations into 2027.

Xenon (XENE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XENE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.99 / -	-0.75	―	―	―
May 12, 2025	2025 (Q1)	-0.90 / -0.83	-0.62	-33.87% (-0.21)	―
Feb 27, 2025	2024 (Q4)	-0.86 / -0.84	-0.64	-31.25% (-0.20)	―
Nov 12, 2024	2024 (Q3)	-0.82 / -0.81	-0.73	-10.96% (-0.08)	―
Aug 08, 2024	2024 (Q2)	-0.70 / -0.75	-0.72	-4.17% (-0.03)	―
May 09, 2024	2024 (Q1)	-0.66 / -0.62	-0.63	1.59% (+0.01)	―
Feb 29, 2024	2023 (Q4)	-0.76 / -0.64	-0.57	-12.28% (-0.07)	―
Nov 08, 2023	2023 (Q3)	-0.77 / -0.73	-0.57	-28.07% (-0.16)	―
Aug 09, 2023	2023 (Q2)	-0.70 / -0.72	-0.55	-30.91% (-0.17)	―
May 09, 2023	2023 (Q1)	-0.62 / -0.63	-0.35	-80.00% (-0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XENE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2025	$35.85	$29.60	-17.43%
Feb 27, 2025	$38.31	$37.02	-3.37%
Nov 12, 2024	$43.39	$41.97	-3.27%
Aug 08, 2024	$41.01	$39.70	-3.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xenon Pharmaceuticals (XENE) report earnings?

Xenon Pharmaceuticals (XENE) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is Xenon Pharmaceuticals (XENE) earnings time?

Xenon Pharmaceuticals (XENE) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XENE EPS forecast?

XENE EPS forecast for the fiscal quarter 2025 (Q2) is -0.99.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing